In this issue:
Enzalutamide in biochemically recurrent prostate cancer
177Lu-PSMA-617 + maintenance pembrolizumab for mCRPC
Oncologic risk of MRI-targeted and systematic biopsies
Genomic profiling of mCRPC samples resistant to androgen receptor inhibitors
Genomic testing effect on urologists' treatment preference
Testosterone replacement and conversion to active treatment on AS
Long-term outcomes after radical prostatectomy +/- radiation
Cancer cribriform architecture detection on prostate MRI
Enzalutamide vs abiraterone for mCRPC based on comorbid diseases
Presurgical 68Ga-PSMA-11 for biochemical recurrence risk assessment
Please login below to download this issue (PDF)